CW
NBIX icon

CreativeOne Wealth’s Neurocrine Biosciences NBIX Stock Holding History

CreativeOne Wealth’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.82M Buy
10,814
+1,647
+18% +$244K 0.04% 380
2026
Q1 		$1.21M Sell
9,167
-460
-5% -$61K 0.03% 504
2025
Q4 		$1.37M Buy
9,627
+1,812
+23% +$263K 0.03% 437
2025
Q3 		$1.1M Sell
7,815
-4,120
-35% -$558K 0.03% 513
2025
Q2 		$1.5M Buy
11,935
+2,350
+25% +$269K 0.04% 418
2025
Q1 		$1.06M Buy
9,585
+4,361
+83% +$552K 0.03% 469
2024
Q4 		$713K Sell
5,224
-3,184
-38% -$394K 0.02% 591
2024
Q3 		$969K Buy
8,408
+5,514
+191% +$756K 0.03% 441
2024
Q2 		$398K Sell
2,894
-5,059
-64% -$694K 0.02% 538
2024
Q1 		$1.1M Buy
7,953
+5,730
+258% +$783K 0.04% 357
2023
Q4 		$293K Buy
+2,223
New +$256K 0.02% 512

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

CreativeOne Wealth's NBIX Position: Q2 2026 in Review

CreativeOne Wealth increased its Neurocrine Biosciences (NBIX) stake by 18% in Q2 2026, buying an estimated $244K and bringing the position to 10,814 shares worth $1.82M. The position accounts for 0.04% of the portfolio, ranked #380.

CreativeOne Wealth first reported a position in NBIX in Q4 2023 and has held it in 11 quarters since. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • CreativeOne Wealth held 10,814 shares of Neurocrine Biosciences worth $1.82M as of Q2 2026.
  • CreativeOne Wealth bought 1,647 Neurocrine Biosciences shares in Q2 2026, an estimated $244K.
  • Neurocrine Biosciences made up 0.04% of CreativeOne Wealth's portfolio in Q2 2026, its #380 holding.
  • CreativeOne Wealth first reported a position in Neurocrine Biosciences in Q4 2023 and has held it in 11 quarters since.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on CreativeOne Wealth's 13F filing for Q2 2026, filed 13 Aug 2026.